SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an ex ...

Oragenics is a biotechnology company focused on developing intranasal therapeutics for neurological disorders. Its lead candidate, ONP-002, is being developed for the treatment of mild traumatic brain injury (mTBI), commonly known as concussion. The Company's intranasal delivery technology is designed to deliver fast, targeted, and non-invasive therapy to the brain. For more information, please visit www.oragenics.com. SARASOTA, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), ...

SARASOTA, Fla., May 28, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a biotech company advancing innovative treatments for brain-related health conditions, today announced that its Board of Directors (the "Board") on May 27, 2025 approved a One-for- Thirty (1-for-30) reverse stock split of the Company's issued and outstanding shares of common stock, par value $0.001 per share (the "Reverse Stock Split"). As a result of the Reverse Stock Split, the Company's ...

文章核心观点 - 奥ragenics公司获得澳大利亚人体研究伦理委员会批准，启动ONP - 002治疗轻度创伤性脑损伤的二期临床试验，有望为脑震荡患者提供治疗选择 [1][2] 公司进展 - 公司获得澳大利亚人体研究伦理委员会批准，可在澳启动ONP - 002治疗轻度创伤性脑损伤的二期临床试验 [1] - 获批后公司最早2025年第二季度开始患者招募，招募和治疗预计在一级创伤急诊科进行 [2] - 公司考虑在澳大利亚和新西兰设置招募点，扩大ONP - 002项目地理覆盖范围 [2] 产品特点 - ONP - 002为鼻内给药，能无创高效将药物输送至大脑 [2] - 临床前模型显示ONP - 002可减少脑震荡相关炎症、氧化应激和脑肿胀 [2] - 一期临床试验表明ONP - 002安全且耐受性良好，有望成为脑震荡急性治疗手段 [2] 公司概况 - 奥ragenics是专注开发神经系统疾病鼻内疗法的生物技术公司，主要候选药物为治疗轻度创伤性脑损伤的ONP - 002 [3] - 公司正在推进专有粉末配方和鼻内给药技术以改善药物施用 [3]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 001-32188 Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ORAGENICS, INC. (Exact name of registrant as specified in its charter) Florida 59-3410522 (State or other jurisdiction of in ...

SARASOTA, Fla., April 09, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today announced that it has submitted a clinical trial protocol for regulatory review to the Health and Disability Ethics Committee (HDEC) in New Zealand. This submission marks a critical milestone in advancing the Company’s Phase II clinical trial evaluating ONP-002, its proprietary neurosteroid therapy, for the trea ...

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA. The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on CNS therape ...

SARASOTA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related disorders, today announced that Chief Medical Officer Dr. James Kelly participated in a panel discussion at the 3rd Nasal Formulation & Delivery Summit, which took place April 1-3, 2025, in Boston, MA. The conference brought together industry leaders to discuss the latest innovations in intranasal drug delivery, with a focus on C ...

SARASOTA, Fla., March 27, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE:OGEN), a biotechnology company focused on developing novel intranasal therapies for brain-related conditions, today provided shareholders with an update on its strategic and financial progress for the first quarter of 2025. The Company has made meaningful advancements across regulatory, clinical, financial, and partnership initiatives, further positioning its lead therapeutic candidate, ONP-002, as a first-in-class solution for treatin ...

文章核心观点 - 奥ragen尼克斯公司宣布向美国证券交易委员会提交2024年年报，其审计报告获无保留意见但有持续经营能力说明 [1][2] 公司情况 - 奥ragen尼克斯是一家专注神经学药物鼻腔递送和抗感染疾病的生物技术公司，有治疗轻度创伤性脑损伤和尼曼匹克病C型的候选药物，还有专有粉末配方和鼻内给药装置 [3] 财务信息 - 公司经审计的合并财务报表获独立注册会计师事务所无保留审计意见，审计包含公司持续经营能力说明，更多细节见申报文件合并财务报表附注1 [2] 年报申报 - 奥ragen尼克斯于2025年3月14日向美国证券交易委员会提交截至2024年12月31日的10 - K表格年度报告 [1] 投资者联系信息 - 投资者可联系Rich Cockrell，电话404.736.3838，邮箱OGEN@CG.CAPITAL [5]